Tema Cardiovascular and Metabolic ETF (HRTS) Fund Overview

Tema Cardiovascular and Metabolic ETF (HRTS) Financial Services Profile

The Tema Heart & Health ETF (HRTS) provides targeted exposure to companies driving innovation in cardiovascular health, metabolic disorders, and weight management within the biotechnology and broader healthcare sectors. This ETF strategically invests in firms developing cutting-edge treatments and therapies, aiming to capitalize on significant advancements in these critical medical areas.

What Is the Investment Thesis for HRTS?

The Tema Cardiovascular and Metabolic ETF (HRTS) offers investors exposure to a specialized segment of the healthcare industry, focusing on companies addressing cardiovascular health, metabolic disorders, and weight management. With a market capitalization of $0.05 billion and a Beta of 0.70, HRTS provides a lower volatility option compared to the broader market, while still tapping into high-growth areas. The primary value driver for HRTS is its strategic investment in firms developing cutting-edge treatments, capitalizing on the increasing global prevalence of these diseases. This demand fuels significant research and development, creating a pipeline of potential growth for the ETF's underlying holdings. Key growth catalysts include ongoing advancements in biotechnology leading to new therapeutic breakthroughs and favorable regulatory environments for drug approvals. However, the ETF's performance is inherently linked to the success of its portfolio companies, which face considerable risks from regulatory hurdles, clinical trial outcomes, and intense competition. Investors should monitor developments in healthcare policy and scientific innovation within these specific disease areas, as these factors will significantly influence the long-term performance trajectory of HRTS.

Based on FMP financials and quantitative analysis

HRTS Key Highlights

Market Capitalization: $0.05 billion, indicating a focused, niche ETF within the asset management sector.

• Beta: 0.70, suggesting lower volatility relative to the broader market, potentially appealing to investors seeking more stable exposure to healthcare innovation.
• Dividend Yield: None, as the ETF does not distribute a dividend, focusing on capital appreciation from its underlying holdings.
• Strategic Investment Mandate: Specifically targets companies developing therapies for cardiovascular health, metabolic disorders, and weight management.
• Exposure to Biotechnology and Healthcare: Provides investors with a diversified basket of companies poised to benefit from cutting-edge developments in these critical industries.

Who Are HRTS's Competitors?

HRTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HRTS's Key Strengths?

Highly focused investment mandate targeting high-growth segments of the healthcare industry.

• Provides diversified exposure to biotechnology and healthcare innovation through an ETF structure.
• Aims to capitalize on the increasing global prevalence of cardiovascular and metabolic diseases.
• Lower Beta (0.70) suggests potentially lower volatility compared to the broader market.

What Are HRTS's Weaknesses?

Small market capitalization of $0.05 billion, which can imply lower liquidity or institutional interest.

• No dividend yield, potentially less attractive for income-focused investors.
• Performance is directly tied to the success and regulatory outcomes of a specialized set of underlying companies.
• Concentration risk within a specific thematic niche of the healthcare sector.

What Are the Key Risks for HRTS?

Regulatory hurdles and the inherent uncertainty of clinical trial outcomes for underlying pharmaceutical and biotech companies, which can significantly impact their valuation.

• Intense competition within the specialized healthcare and thematic ETF markets, potentially leading to pressure on fees or asset flows.
• Adverse changes in healthcare policy, drug pricing regulations, or reimbursement structures that could negatively affect the profitability of portfolio companies.
• Market volatility specific to the biotechnology and healthcare sectors, which can be influenced by scientific breakthroughs, failures, and investor sentiment.

What Are HRTS's Competitive Advantages?

• Specialized Thematic Focus: Offers a unique and concentrated investment mandate specifically targeting cardiovascular health, metabolic disorders, and weight management, differentiating it from broader healthcare funds.
• Diversified Niche Exposure: Provides a diversified basket of companies within its specific niche, reducing single-stock risk while maintaining thematic purity.
• Strategic Investment Approach: Employs a strategic methodology to identify companies poised for growth from cutting-edge developments in its target areas.

What Does HRTS Do?

The Tema Heart & Health ETF (HRTS) operates within the financial services sector as an asset management product, specifically designed to offer investors focused exposure to the rapidly evolving landscape of biotechnology and healthcare. Established with a clear mandate, HRTS strategically invests in companies that are at the forefront of developing innovative treatments and therapies for critical health challenges. Its core investment focus encompasses firms dedicated to advancing cardiovascular health, addressing metabolic disorders, and pioneering solutions for weight management. This specialized approach allows HRTS to target segments of the healthcare market characterized by significant unmet medical needs and robust research and development activity. The ETF's investment philosophy is rooted in identifying companies poised to benefit from cutting-edge scientific discoveries and technological breakthroughs. By concentrating on cardiovascular diseases, metabolic conditions like diabetes, and the growing global issue of obesity, HRTS aims to capture the value generated by advancements in these areas. The increasing prevalence of these diseases globally drives a continuous demand for novel therapeutic and diagnostic solutions, creating a fertile ground for the companies within the ETF's portfolio. While the specific geographic reach of its underlying holdings is diverse, the ETF itself is headquartered in New York, US, reflecting its positioning within the global financial markets. HRTS provides a diversified basket of companies, offering a mechanism for investors to gain exposure to this specialized healthcare niche without the need for individual stock selection, thereby aligning with the broader trend of thematic ETF adoption in asset management. Its competitive positioning stems from its highly specific thematic focus, differentiating it from more generalized healthcare or biotechnology funds by offering a concentrated play on these interconnected health domains. The ETF's evolution reflects the growing investor interest in targeted thematic investments that capitalize on long-term demographic and scientific trends within the healthcare industry.

What Products and Services Does HRTS Offer?

• Invests strategically in companies within the biotechnology and broader healthcare industries.
• Focuses specifically on firms developing treatments and therapies for cardiovascular health.
• Targets companies addressing metabolic disorders, such as diabetes.
• Includes investments in firms pioneering solutions for weight management.
• Provides investors with exposure to cutting-edge developments in these specialized medical fields.
• Operates as an Exchange Traded Fund (ETF), offering a diversified basket of relevant stocks.
• Aims to capitalize on the increasing global prevalence of cardiovascular and metabolic diseases.

How Does HRTS Make Money?

• Generates revenue primarily through management fees (expense ratio) charged to investors for managing the ETF.
• Seeks to provide capital appreciation for investors by investing in a diversified portfolio of companies.
• Does not directly generate revenue from the sales of products or services of its underlying portfolio companies.
• Its success is measured by the performance of its underlying holdings and its ability to attract and retain assets under management (AUM).

What Industry Does HRTS Operate In?

The Tema Cardiovascular and Metabolic ETF (HRTS) operates within the dynamic asset management industry, specifically carving out a niche in thematic exchange-traded funds. The broader financial services sector has seen a significant trend towards specialized ETFs that offer targeted exposure to specific market segments or megatrends. HRTS positions itself by focusing exclusively on companies involved in cardiovascular health, metabolic disorders, and weight management, areas experiencing substantial growth due to increasing disease prevalence globally. This strategic focus differentiates it from general healthcare or biotechnology ETFs, allowing it to cater to investors seeking concentrated exposure to these interconnected medical fields. The competitive landscape includes numerous other healthcare and thematic ETFs, but HRTS aims to stand out through its precise investment mandate. The demand for innovative treatments in its target areas is robust, driven by an aging population and lifestyle changes, suggesting a sustained market for its underlying investments.

Who Are HRTS's Key Customers?

• Institutional investors seeking thematic exposure to specialized healthcare segments.
• Retail investors looking for diversified access to biotechnology and healthcare innovation.
• Investors focused on long-term growth trends in cardiovascular and metabolic health.
• Portfolio managers aiming to complement existing allocations with targeted healthcare exposure.

HRTS Financials

HRTS Latest News

No recent news available for HRTS.

HRTS Analyst Consensus

HRTS MoonshotScore

Tema Cardiovascular and Metabolic ETF Financials Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources